157 related articles for article (PubMed ID: 35625789)
1. Gene Polymorphism of Biotransformation Enzymes and Ciprofloxacin Pharmacokinetics in Pediatric Patients with Cystic Fibrosis.
Zyryanov SK; Ushkalova EA; Kondratyeva EI; Butranova OI; Kondakova YA
Biomedicines; 2022 May; 10(5):. PubMed ID: 35625789
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of ciprofloxacin in pediatric cystic fibrosis patients.
Schaefer HG; Stass H; Wedgwood J; Hampel B; Fischer C; Kuhlmann J; Schaad UB
Antimicrob Agents Chemother; 1996 Jan; 40(1):29-34. PubMed ID: 8787874
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation.
Rubio TT; Miles MV; Lettieri JT; Kuhn RJ; Echols RM; Church DA
Pediatr Infect Dis J; 1997 Jan; 16(1):112-7; discussion 123-6. PubMed ID: 9002120
[TBL] [Abstract][Full Text] [Related]
4. Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers.
Kirchheiner J; Meineke I; Müller G; Roots I; Brockmöller J
Pharmacogenetics; 2002 Oct; 12(7):571-80. PubMed ID: 12360109
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis.
Montgomery MJ; Beringer PM; Aminimanizani A; Louie SG; Shapiro BJ; Jelliffe R; Gill MA
Antimicrob Agents Chemother; 2001 Dec; 45(12):3468-73. PubMed ID: 11709326
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacokinetics of ciprofloxacin in patients with major burns.
Lesne-Hulin A; Bourget P; Ravat F; Goudin C; Latarjet J
Eur J Clin Pharmacol; 1999 Sep; 55(7):515-9. PubMed ID: 10501821
[TBL] [Abstract][Full Text] [Related]
7. Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study.
Stass H; Weimann B; Nagelschmitz J; Rolinck-Werninghaus C; Staab D
Clin Ther; 2013 Oct; 35(10):1571-81. PubMed ID: 24054830
[TBL] [Abstract][Full Text] [Related]
8. CYP2C9*3(1075A > C), ABCB1 and SLCO1B1 genetic polymorphisms and gender are determinants of inter-subject variability in pitavastatin pharmacokinetics.
Zhou Q; Chen QX; Ruan ZR; Yuan H; Xu HM; Zeng S
Pharmazie; 2013 Mar; 68(3):187-94. PubMed ID: 23556337
[TBL] [Abstract][Full Text] [Related]
9. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers.
Kirchheiner J; Kudlicz D; Meisel C; Bauer S; Meineke I; Roots I; Brockmöller J
Clin Pharmacol Ther; 2003 Aug; 74(2):186-94. PubMed ID: 12891229
[TBL] [Abstract][Full Text] [Related]
10. ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics.
Zhou Q; Ruan ZR; Yuan H; Xu DH; Zeng S
Pharmazie; 2013 Feb; 68(2):129-34. PubMed ID: 23469685
[TBL] [Abstract][Full Text] [Related]
11. [Spontaneous bacterial peritonitis in liver cirrhosis: optimization issues of prevention and treatment].
Vinnitskaia EV; Drozdov VN; Petyrakov AV; Sil'vestrova SIu; Brezgin AG
Eksp Klin Gastroenterol; 2012; (6):27-34. PubMed ID: 23402188
[TBL] [Abstract][Full Text] [Related]
12. Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. The Cystic Fibrosis Study Group.
Church DA; Kanga JF; Kuhn RJ; Rubio TT; Spohn WA; Stevens JC; Painter BG; Thurberg BE; Haverstock DC; Perroncel RY; Echols RM
Pediatr Infect Dis J; 1997 Jan; 16(1):97-105; discussion 123-6. PubMed ID: 9002118
[TBL] [Abstract][Full Text] [Related]
13. CYP2C9*3(1075A>C), MDR1 G2677T/A and MDR1 C3435T are determinants of inter-subject variability in fluvastatin pharmacokinetics in healthy Chinese volunteers.
Zhou Q; Ruan ZR; Yuan H; Zeng S
Arzneimittelforschung; 2012 Nov; 62(11):519-24. PubMed ID: 22941809
[TBL] [Abstract][Full Text] [Related]
14. Enantioselective pharmacokinetics of racemic carprofen in New Zealand white rabbits.
Hawkins MG; Taylor IT; Craigmill AL; Tell LA
J Vet Pharmacol Ther; 2008 Oct; 31(5):423-30. PubMed ID: 19000261
[TBL] [Abstract][Full Text] [Related]
15. Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers.
Kirchheiner J; Meineke I; Müller G; Bauer S; Rohde W; Meisel C; Roots I; Brockmöller J
Clin Pharmacokinet; 2004; 43(4):267-78. PubMed ID: 15005635
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and bioequivalence of two formulations of rebamipide 100-mg tablets: a randomized, single-dose, two-period, two-sequence crossover study in healthy Korean male volunteers.
Cho HY; Yoon H; Park GK; Lee YB
Clin Ther; 2009 Nov; 31(11):2712-21. PubMed ID: 20110013
[TBL] [Abstract][Full Text] [Related]
17. Ciprofloxacin pharmacokinetics in young cystic fibrosis patients after repeated oral doses.
Odoul F; Le Guellec C; Giraut C; de Gialluly C; Marchand S; Paintaud G; Saux MC; Rolland JC; Autret-Leca E
Therapie; 2001; 56(5):519-24. PubMed ID: 11806288
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of chlorpyrifos and 3,5,6-trichloro-2-pyridinol in rat saliva after chlorpyrifos administration.
Smith JN; Wang J; Lin Y; Klohe EM; Timchalk C
Toxicol Sci; 2012 Dec; 130(2):245-56. PubMed ID: 22874420
[TBL] [Abstract][Full Text] [Related]
19. Effect of Genetic Variation of
Dompreh A; Tang X; Zhou J; Yang H; Topletz A; Adu Ahwireng E; Antwi S; Enimil A; Langaee T; Peloquin CA; Court MH; Kwara A
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263072
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of cefepime in cystic fibrosis patients.
Huls CE; Prince RA; Seilheimer DK; Bosso JA
Antimicrob Agents Chemother; 1993 Jul; 37(7):1414-6. PubMed ID: 8363368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
